Abstract

 CADTH recommends that Retevmo be reimbursed by public drug plans for the treatment of adults with advanced or metastatic rearranged during transfection (RET) fusion-positive differentiated thyroid cancer (DTC) if certain conditions are met.
 Retevmo should only be covered to treat patients who have advanced or metastatic DTC (not amenable to surgery or radioactive iodine therapy) with the RET mutation and have had prior treatment with sorafenib and/or lenvatinib. Patients receiving Retevmo should be in relatively good health (i.e., have a good performance status, as determined by a specialist).
 Retevmo should only be reimbursed if it is prescribed by a specialist, the patients' cancer is RET positive, it is not given in combination with other anticancer drugs, and the price is reduced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
